ABSTRACT
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the COVID-19 disease, which is a considerable outbreak that appeared in late 2019, and within a short period, this disease rapidly extended globally. Its prompt airborne transmission and highly infectious pneumonia-like symptoms in patients caused turmoil worldwide. This virus has a relatively high mortality rate compared to previous outbreaks such as Middle East respiratory syndrome coronavirus and SARS-CoV. Therefore, the World Health Organization declared COVID-19 a global health pandemic on January 30, 2020. However, the recent COVID-19 outbreak and newly emerged variants such as Delta and Omicron are having a huge spike in the human population. This rise has been a kind of challenging situation worldwide as perception is still limited in terms of modes of transmission, severity, diagnostics clinical oversight. Therefore, this review highlights the importance of these issues via a Medline search using the terms novel, coronavirus, sources, genetic nature, contagious routes, clinical characteristics, and diagnostic procedures for COVID-19. The authors extensively reviewed the analysis of behavior and impacts of this virus’s activities worldwide. The study reveals that patients’ epidemiology and clinical characteristics in different frames are sensitive toward commanding this virus and its associated diseases. Finally, the parametric data gathered for this study are also presented for use in forecasting models. Along with these searches, the authors have comprehensively discussed the current modern diagnostic processes. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
COVID-19 and the Sustainable Development Goals: Societal Influence explores how the coronavirus pandemic impacts the implementation of the UN’s Sustainable Development Goals (SDG), paying particular attention to socioeconomic and disaster risk management dimensions. Sections provide a foundational understanding of the virus and its risk factors, cover relevant mitigation measures for minimizing the spread of COVID-19, explore the virus’s originations and transmission mechanisms, and look at gold standard procedures for COVID-19 testing and antibody-based diagnosis. Final sections present the latest insights on the global effects of COVID-19 and examine potential future challenges, opportunities and strategic responses. © 2022 Elsevier Inc. All rights reserved.
ABSTRACT
OBJECTIVE: To review cases of acute macular neuroretinopathy (AMN) after COVID-19 vaccination and add a similar case to the literature. METHODS: A thorough PubMed search was conducted, and data from studies describing AMN after COVID-19 vaccination were extracted, tabulated, pooled, and reviewed. RESULTS: We present a case of AMN in a young woman 5 days after immunization with the BBIBP-CorV (Sinopharm) COVID-19 vaccine. Data from 21 cases were pooled and reviewed. The most frequent vaccines among the cases were recombinant ones (13/21), followed by mRNA-based (6/21) and inactivated vaccines (2/21). Only one patient (5%) was male. Seventeen over twenty-one (81%) were young women, ages 18-33. Most cases (14/21; 67%) reported recent/concurrent use of contraceptive medication. In 90% of cases (19/21), symptoms appeared within 8 days of vaccination. A confined wedge-/oval-shaped lesion morphology was more frequent than a diffuse, semilunar one. Resolution of symptoms took 4 to over 15 weeks. CONCLUSION: Attention should be paid to the history of vaccination and contraceptive use in patients with sudden-onset visual symptoms. Optical coherence tomography is integral to the detection of AMN-related abnormalities.
Subject(s)
COVID-19 Vaccines , COVID-19 , White Dot Syndromes , Adolescent , Adult , Female , Humans , Male , Young Adult , Acute Disease , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Vaccination/adverse effectsABSTRACT
Background: The COVID-19 pandemic has led to more than 260 million infections and 55 million deaths as of early December 2021, worldwide. Vaccinating people against COVID-19 is considered as he best approach to overcome the pandemic since COVID 19-vaccines are effective and can reduce the risk of getting and spreading the virus. However, their efficacy and safety in patients with underlying disease such as cancers have not been approved yet. Here we report a cohort study on immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer, who were vaccinated as a part of a national plan for vaccination of patients with special diseases.
ABSTRACT
Background and Aim: The COVID-19 epidemic control has become a global challenge and many contributing variables are still unknown to policymakers. This case-cohort study was conducted to investigate the risk factors of mortality in COVID-19 patients.